Compare HSBC Holdings plc (HSBC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HSBC Holdings plc vs State Street SPDR S&P Biotech ETF — how do they compare? HSBC Holdings plc trades at $104 (market cap $353.82B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: HSBC Holdings plc pays a 3.63% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| HSBC | XBI | |
|---|---|---|
Market Cap | $353.82B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $107.86 | $164.28 |
52-Week Low | $63.84 | $86.92 |
Dividend Yield | 3.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HSBC trades at $104.12, up 0.77% today, with a bullish technical signal from moving averages and support near $103. The bank reported strong Q2 2026 results with a 7% revenue increase and a $1 billion buyback, while net income margin improved to 34.54% in 2026. Analyst sentiment is mixed, with 38.1% buy ratings, but recent news includes a Citi downgrade citing a 40% stock run-up.
The outlook remains positive due to earnings momentum and shareholder returns, but risks include China regulatory changes and valuation concerns after the recent rally. Further upside depends on sustained revenue growth and effective capital allocation.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
